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, Andrew F. Shorr, MD, MPHc, William M. Jesdale, PhDd,
Jennifer Tjia, MD, MSCEd, Kate Lapane, PhDd
Abstract
We explored the epidemiology and outcomes of Clostridium difﬁcile infection (CDI) recurrence among Medicare patients in a nursing
home (NH) whose CDI originated in acute care hospitals.
We conducted a retrospective, population-based matched cohort combining Medicare claims with Minimum Data Set 3.0,
including all hospitalized patients age ≥65 years transferred to an NH after hospitalization with CDI 1/2011-11/2012. Incident CDI
was deﬁned as ICD-9-CM code 008.45 with no others in prior 60 days. CDI recurrence was deﬁned as (within 60 days of last day
of CDI treatment): oral metronidazole, oral vancomycin, or ﬁdaxomicin for ≥3 days in part D ﬁle; or an ICD-9-CM code for CDI
(008.45) during a rehospitalization. Cox proportional hazards and linear models, adjusted for age, gender, race, and
comorbidities, examined mortality within 60 days and excess hospital days and costs, in patients with recurrent CDI compared to
those without.
Among 14,472 survivors of index CDI hospitalization discharged to an NH, 4775 suffered a recurrence. Demographics and
clinical characteristics at baseline were similar, as was the risk of death (24.2% with vs 24.4% without). Median number of
hospitalizations was 2 (IQR 1–3) among those with and 0 (IQR 0–1) among those without recurrence. Adjusted excess hospital
days per patient were 20.3 (95% CI 19.1–21.4) and Medicare reimbursements $12,043 (95% CI $11,469–$12,617) in the group
with a recurrence.
Although recurrent CDI did not increase the risk of death, it was associated with a far higher risk of rehospitalization, excess hospital
days, and costs to Medicare.
Abbreviations: CDI = Clostridium difﬁcile infection, LOS = length of stay, MDS =Minimum Data Set, NH = nursing home, SNF =
skilled nursing facility.
Keywords: C. difﬁcile, costs, hospitalization, Medicare, nursing home, recurrence
1. Introduction
One of the most challenging aspects in the care of patients with
Clostridium difﬁcile infection (CDI) is its potential to recur. In
some cases recurrence follows exposure to additional courses of
antimicrobials, while in others there is no clear inciting event. In
general, multiple lines of evidence, including a meta-analysis,
randomized controlled trials of CDI therapies, and cohort
studies, indicate that the rates of recurrence in this infection range
from approximately 10% in hospitalized populations to 50% in
other groups.[1–4]
Older age represents a well-established risk factor for
developing CDI.[5–9] In turn, this suggests that a large and
growing proportion of the population faces some risk for a CDI
recurrence. Due to age and frailty, the elderly are more prone
than the young to come in contact with a nursing home (NH),
where the overall prevalence of a CDI diagnosis is 2.1% and rates
of asymptomatic carriage of toxigenic C. difﬁcile are nearly
50%.[10,11] Despite such high colonization rates, studies suggest
that a small minority of CDI in NHs originates from long-term
NH dwellers. In fact, up to 90% of all NH-related CDI can be
traced to patients transferred to the NH from acute care
hospitals.[11–14]
Little is known about this population of patients, who, by
surviving CDI in acute care, serve as a potential reservoir for
spreading this infection within NHs after transfer. Furthermore,
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to the best of our knowledge no study has examined the risk of
recurrence speciﬁcally in this group. Understanding the epidemi-
ology and outcomes of recurrence among these patients is crucial
in order to improve infection control practices in NHs, and to
develop strategies to limit the costs associated with recurrences.
Therefore, we examined the frequency of recurrent CDI and its
relationship with hospitalization, mortality, and costs in a group




We conducted a retrospective, population-based matched cohort
study of NH residents hospitalized with CDI and discharged to a
nursing facility after the index event. Episodes of CDI were
identiﬁed using a validated case identiﬁcation approach (de-
scribed below). We explored the research identiﬁable Medicare
claims data (enrollment ﬁle and parts A, B, and D) linked to
Minimum Data Set (MDS) 3.0 data. This study was approved by
the University of Massachusetts Medical School Institutional
Review Board.
2.2. Description of data sources
See Supplemental Appendix 1 for detailed data source descrip-
tion, http://links.lww.com/MD/B587.
2.3. Cohort deﬁnition
The cohort consisted of elderly (age ≥65 years) patients from the
entire population of the United States and its Atlantic island
territories. Subjects had to survive a hospitalization with an
incident CDI episode in an acute care setting and to be discharged
to an NH (Fig. 1). We further required a full NH admissionMDS
assessment. All index hospitalizations occurred betweenMarch 1
and December 31, 2011, after 60 days of both continuous co-
enrollment inMedicare parts A, B, andD and absence of evidence
of CDI on MDS or inpatient records. An index episode of CDI
was deﬁned by the presence of an ICD-9-CM code of 008.45 on
any hospitalization at an acute care facility during the March to
December period.
2.4. CDI episodes
CDI was considered incident if there was no evidence of CDI in
the previous 60 days. Each incident CDI episode was classiﬁed as
community-acquired (CA) if there was a CDI code in the
“present on admission” ﬁeld, and no evidence of a previous
admission to another hospital, skilled nursing facility (SNF), or
an NH within 12 weeks of the index admission date.[15] A
community-onset healthcare facility associated event occurred if
there was a CDI code in the “present on admission” ﬁeld, and
the patient was transferred from another healthcare facility or
had evidence of admission to another hospital, SNF, or an NH
within 4 weeks of the index admission date. The index CDI
episode was deemed hospital-onset healthcare facility associated
if there was no CDI code in the “present on admission” ﬁeld.[16]
Those patients with a CDI code in the “present on admission”
ﬁeld and evidence of admission to another hospital, SNF, or a
NH within 4 to 12 weeks of the index admission date were
classiﬁed as “indeterminate.”
CDI recurrence was deﬁned by one of the following occurring
within 60 days from index discharge or of the last day of incident
CDI treatment in the NH: 1. Note of treatment with oral
metronidazole, oral vancomycin, or ﬁdaxomicin for at least 3
Figure 1. Enrollment and observation timeline for a hypothetical patient in the cohort
∗
. CDI=Clostridium difﬁcile infection. Pathway for a hypothetical patient
enrolled in the cohort. This patient’s index hospitalization with an incident CDI begins on March 1 after 60 days of observation to establish appropriate Medicare
enrollment and CDI-free period. Discharge occurs on hospital day 23, when the observation period for 30-day rehospitalization as well as a recurrence within 60
days commences. In this hypothetical patient, a recurrent CDI is noted on day 30 following index discharge. At this point, observation period for a 30-day
rehospitalization and 60-day mortality begins.
∗
Each block signiﬁes duration of the corresponding event (numbers inside are days).
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days at the NH in the part D ﬁle, or 2. An ICD-9-CM code for
CDI (008.45) during a repeat hospitalization. To distinguish a
recurrence from persistence, we required a gap of at least 7 days
in drug administration at the NH after discontinuation of
treatment for the index episode of CDI.
2.5. Main exposure and covariate measures
Demographic (age, gender, and race/ethnicity) and clinical (acute
illness severity [sepsis, toxic megacolon, bowel perforation,
colectomy, and intensive care unit stay] and comorbidity burden
[individual comorbidities and Charlson comorbidity index])
characteristics for the cohort were collected during the index
hospitalization.
2.6. Outcome measures
We examined rehospitalization rates within 30 days of a
recurrence, time to rehospitalization, hospital length of stay
(LOS) and costs (measured as Medicare payments in $US) for
the initial postrecurrence rehospitalization, and 60-day
mortality in patients with recurrent CDI compared to those
without (Fig. 1). The observation period was extended to 60
days to compute the number of hospitalizations per patient
over time, and cumulative per-patient hospital days and costs.
The latter 2 outcome variables were derived by summing
across all part A events (hospitalizations at acute care
facilities, other types of hospitals, and Medicare-reimbursed
short-stay SNF stays) that began within 60 days of the onset
of recurrence, including those hospitalizations that deﬁned the
recurrence event, and those that extended beyond the end of
the 60 day window.
2.7. Statistical analyses
We used descriptive statistics to characterize the group of NH
residents with a recurrent CDI who were matched (with
replacement) to those without a recurrence based on the date of
discharge from the index hospitalization in order to create
comparable time periods of observation. Patients were matched
on discharge date from the index hospitalization, conditional
on survival until the matched case’s recurrence date, to ensure
comparable levels of follow-up available for outcome ascer-
tainment from the recurrence date forward. We used the
GREEDY algorithm to match as many controls as possible to
each case with replacement.[17] Thus, the 9704 potential
controls could be matched to more than 1 case, resulting in
13,736 matches, with a range of 1 to 25, and a median of 3
matches per case. Those without a recurrence were eligible for
inclusion if they were alive on the day recurrence was noted in
the comparator group, either via a repeat CDI ICD-9-CM code
or based on medication usage at the NH. Due to the limited
utility of statistical testing in a sample this large, we elected to
consider a prevalence difference of 5% worthy of note.
Although the clinical difference of 5% is somewhat arbitrary, it
is well within the range that most clinicians would consider an
important difference.
We derived Cox proportional hazards (to examine 30-day
rehospitalization and 60-day mortality risks) and linear (to
compute excess cumulative 60-day hospital days and costs)
models adjusting for age, gender, race, and comorbidities, in
patients with recurrent CDI compared to those without a
recurrence.
3. Results
3.1. Recurrence rates and baseline patient characteristics
Among 14,472 patients who survived their index CDI hospitali-
zation and were discharged to a NH, 4775 (33.0%) suffered a
recurrence. Of those, 4768 (99.9%) were matched to 13,736
without a recurrence (weighted to 4768). Those with and without
a recurrence were similar in age, gender, and race/ethnicity
(Table 1). Similarly, there were no substantive differences
between the groups in the distribution of comorbid conditions
or the Charlson comorbidity index. Although those without a
recurrence were more likely to have their index CDI classiﬁed as
hospital-acquired than those with a subsequent recurrence
(25.2% vs 18.3%), the situation was reversed for the unknown
acquisition category (27.7% vs 32.6%, respectively) (Table 1).
3.2. Events during index hospitalization
Although frequency of sepsis during the index hospitalization
was similar in the 2 groups, the need for intensive care unit care
was more common among those who did not (29.0%) than those
who did (24.5%) experience a recurrence (Table 2). Although the
rate of colectomy was 2-fold higher in the nonrecurrent than
recurrent group, this procedure was rare in both (Table 2). As for
unadjusted hospital LOS and costs of the index hospitalization,
both were numerically higher in the non-recurrence group than in
those with a recurrence (Table 2). Notably, however, the risk of
rehospitalization within 30 days of the index discharge among
patients with any eventual CDI recurrence during our study time
horizon (64.9%) was more than triple that among those without
(17.8%).
3.3. Recurrence outcomes
In contrast, within 30 days of the CDI recurrence (Fig. 1),
hospitalization occurred in 28.1%of the individuals compared to
17.8% in the same timeframe among those without a recurrence,
and median time to hospitalization was similar between the 2
groups (13 days with recurrence vs 12without) (Table 3). The 60-
day mortality in the 2 groups was also similar (24.2% vs 24.4%).
In the adjusted analysis, CDI recurrence was associated with a
67% (95% CI 55%–79%) increase in the hazard of 30-day
rehospitalization (Table 4). Although neither hospital LOS nor
costs per ﬁrst postrecurrence hospitalization differed substan-
tively among those who were rehospitalized, the cumulative
burden of hospitalizations in the group that recurred far exceeded
that in the group that did not (Table 3). Consistent with this, the
adjusted excess hospital days per patient were 20.3 (95% CI
19.1–21.4) and costs were $12,043 (95% CI $11,469–$12,617)
compared to those without a recurrence (Table 4).
4. Discussion
In the current study of older patients whose incident CDI
occurred during a hospitalization that ended in a discharge to an
NH, all survivors of such hospitalization had a 33% risk of
developing a recurrent bout of CDI within 60 days following
discharge or termination of anti-CDI therapy. Although there
were no dramatic differences noted during the index hospitaliza-
tion between those who recurred and those who did not, the
group with an eventual recurrence had a nearly 4-times the risk of
those without a recurrence of a 30-day readmission following
discharge from the index hospitalization, whether with the CDI
Zilberberg et al. Medicine (2017) 96:10 www.md-journal.com
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recurrence or preceding it. Similarly, the risk of a repeat
hospitalization following recurrent CDI was signiﬁcantly higher
in the group with than the matched group without a recurrence.
Although per hospitalization LOS and costs did not differ
between the groups, because of the increased likelihood of
admission in the recurrence group, the cumulative 60-day excess
rehospitalization days (∼20) and costs (∼$12,000) were high,
suggesting the economic burden for Centers for Medicare and
Medicaid Services in conjunction with CDI recurrence in the NH
population is substantial and likely to expand with the aging of
the population.
Pepin et al[18] examined the course of recurrent CDI in a
Canadian cohort of over 460 patients treated between 1991 and
2005. Of these, 9.3% suffered death within 30 days of
recurrence. A more recent mixed (in- and outpatient) cohort
study from Scotland found 16.4% mortality within 1 year of the
onset of incident infection in those with a recurrence compared to
only 0.5% among those without.[19] Last, Olsen et al[20]
examined 180-day mortality in a cohort of patients with a
CDI that recurred following an incident CDI hospitalization. In
this investigation, a recurrence raised the adjusted risk of death by
over 33%. In contrast, we did not detect a difference in 60-day
mortality. This important divergence suggests that, at the very
least, age (our cohort is substantially older than others) and
possibly non-CDI illness burden (marked by needing a discharge
to a NH following their index hospitalization), may modify the
effect of CDI recurrence on mortality. Although it would be of
interest to examine causes of death, we did not have access to this
information.
Only a handful of studies have taken a detailed look at
rehospitalizations associated with CDI recurrence among
patients with CDI.[21–23] In one from a large urban academic
medical center, among nearly 4000 patients with an incident
CDI, 11% developed a documented recurrence.[21] Patients with
a recurrence (85%) were approximately twice as likely as those
without (41%) to require a rehospitalization within 180 days
following their initial bout of CDI. The 2nd study focused on
critically ill patients by asking whether an early recurrence of CDI
Table 1
Characteristics at the time of index hospitalization of patients with and without a recurrent episode of Clostridium difﬁcile infection.
Recurrence+ (n=4768) Recurrence (n=4768)∗
Mean (IQR)/Median (SD) % of subjects Mean (IQR)/Median (SD) % of subjects
Age, years





Asian, Native Hawaiian, or other Paciﬁc Islander 1.6% 1.9%
American Indian or Alaska Native 0.4% 0.4%
Another race 0.4% 0.3%
Hispanic 5.6% 5.9%
Comorbid conditions
Myocardial infarction 9.2% 9.0%
Congestive heart failure 29.6% 30.5%
Peripheral vascular disease 11.7% 11.7%
Cerebrovascular disease 10.8% 12.7%
Dementia 8.9% 11.1%
Chronic obstructive pulmonary disease 27.8% 28.4%
Rheumatological disease 3.7% 4.1%
Peptic ulcer disease 2.2% 2.5%
Mild liver disease 2.0% 2.6%
Moderate or severe liver disease 0.5% 0.7%
Diabetes without chronic complication 26.2% 26.8%
Diabetes with chronic complication 5.8% 5.6%
Hemiplegia or paraplegia 1.9% 2.3%
Renal disease 27.9% 28.5%
Malignancy 8.5% 9.0%
Metastatic solid tumor 2.3% 2.7%
HIV/AIDS 0.0% 0.1%
Weight loss 18.1% 20.1%
Fluid and electrolyte disorders 48.4% 51.4%
Charlson comorbidity index score
Median (IQR 25, 75) 3 (1, 5) 3 (1, 5)
Incident CDI classiﬁcation
Hospital acquired 18.3% 25.2%
Community onset healthcare facility acquired 27.7% 27.3%
Community acquired 0.7% 1.7%
Community onset-indeterminate 20.7% 18.1%
Unknown 32.6% 27.7%
AIDS= acquired immune deﬁciency syndrome, CDI=Clostridium difﬁcile infection, HIV=human immunodeﬁciency virus, IQR= interquartile range.
∗
Weighted by the inverse of the number of “no recurrence” cases matched to each recurrent case on the date of discharge from the initial hospitalization. Unweighted n=13,736.
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impacts 30-day rehospitalization.[22] Indeed the investigators
reported a signiﬁcant elevation in the risk of rehospitalization in
the face of a recurrence, with the adjusted odds ratio exceeding
15. Our numbers, though more modest, comport with those
studies in terms of the relative rise in readmission associated with
CDI recurrence. The far lower magnitude of the problem as
detected in the current study is likely due to a combination of
several factors. First, there were important population differ-
Table 2
Index hospitalization illness severity, complications, and outcomes.
Recurrence+ (n=4768) Recurrence (n=4768)∗
Mean (IQR)/Median (SD) % of subjects Mean (IQR)/Median (SD) % of subjects
Indicators of illness severity
ICU during admission 24.5% 29.0%
Sepsis 21.1% 22.5%
Hospital complications
Toxic megacolon 1.0% 0.9%
Bowel perforation 0.0% 0.1%
Colectomy 1.1% 2.2%
Hospital LOS, days
Mean (SD) 16.3 (19.6) 19.6 (14.2)
Median (IQR 25, 75) 12 (7, 20) 13 (7, 23)
Hospital costs, $
Mean (SD) $9801 ($14,533) $12,936 ($10,974)
Median (IQR 25, 75) $6722 ($767, $12,424) $8295 ($1805, $15,310)
30-day readmission† 64.9% 17.8%
ICU= intensive care unit, IQR= interquartile range, LOS= length of stay, SD= standard deviation.
∗
Weighted by the inverse of the number of “no recurrence” cases matched to each recurrent case on the date of discharge from the initial hospitalization. Unweighted n=13,736.
† Readmission within 30 days of discharge from initial hospitalization.
Table 3
Unadjusted outcomes among those with and without CDI recurrence.
Recurrence+ (n=4768) Recurrence (n=4768)∗
N/mean/median SD/IQR/% N/mean/median SD/IQR/%
Hospitalization within 30 days postrecurrence 1340 28.1% 842 17.8%
Days to hospitalization following recurrence
1–6 98 2.1% 42 0.9%
7–13 296 6.2% 213 4.5%
14–20 308 6.5% 214 4.5%
21–30 320 6.7% 173 3.6%
Time to ﬁrst postrecurrence hospitalization, days
Mean (SD) 13.1 (8.8) 12.8 (5.2)
Median (IQR 25, 75) 13 (5, 20) 12 (5, 20)
First postrecurrence hospitalization LOS, days
Mean (SD) 7.5 (7.3) 6.5 (3.9)
Median (IQR 25, 75) 5 (3, 9) 5 (3, 8)
First postrecurrence hospitalization costs, $
Mean (SD) $8771 ($18,050) $9162 ($6980)
Median (IQR 25, 75) $6641 ($1158, $10,868) $6966 ($3205, $11,566)
Cumulative hospitalization parameters within 60 days post recurrence onset
Median (IQR 25, 75) number of hospitalization events per patient 2 (1, 3) 0 (0, 1)
Cumulative per patient hospital LOS, days†
Mean (SD) 31.4 (45.6) 11.0 18.8
Median (IQR 25, 75) 17 (4, 47) 0 (0, 7)
Cumulative per patient hospital costs, $†
Mean (SD) $17,849 ($24,867) $5755 ($8005)
Median (IQR 25, 75) $10,456 ($0, $28,400) $0 ($0, $4812)
60 day mortality 24.2% 24.4%
Time to death, days
Mean (SD) 26.5 (17.0) 22.4 (9.5)
Median (IQR 25, 75) 26 (11, 41) 19 (9, 34)
CDI=Clostridium difﬁcile infection, ICU= intensive care unit, IQR= interquartile range, LOS= length of stay, SD= standard deviation.
∗
Weighted by the inverse of the number of “no recurrence” residents matched to each resident with recurrent CDI on the date of discharge from the initial hospitalization, and still alive on the day of discharge from
the 2nd hospitalization (if recurrence identiﬁed on readmission), or the day of recurrence (if identiﬁed via medication usage). Unweighted n=13,736 for mortality outcome and 13,644 for the 30-day readmission
outcome because we required residents to be alive on the day of discharge from the 2nd hospitalization.
† Includes recurrence-deﬁning hospitalizations, and hospitalizations that start within 60 days of the recurrence date, even if the discharge date is after 60 days.
Zilberberg et al. Medicine (2017) 96:10 www.md-journal.com
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ences, particularly given that one of the studies was conﬁned to
the critically ill. Second, our observation timeframe of 60 days
was only 1/3 of Olsen et al. It is likely that with a longer
observation period we would have detected a higher rate of
readmission in both groups.
Olsen et al[21] additionally compared numbers of hospital-
izations and numbers of hospital days in the 180-day follow-up
period between the group that experienced a recurrence and one
that did not. In each comparison, the group with a recurrence
fared worse than the group without. Namely, the group with a
recurrence incurred an excess of 11 days over those without, and
the number of readmissions per patient was 1.72 versus 0.81 for
the groups, respectively. Recurrent CDI had an independent
impact on these outcomes. Our observations are consistent with
those investigators’ in that the group with a recurrence was
substantially more likely to experience a rehospitalization, and
this resulted in an average excess of 20 days in the hospital for a
patient with a recurrence over 60 days following the onset of said
recurrence. Although this number of excess days is higher than
previously reported, it is not surprizing given the elderly NH
population in our study.
Finally, Dubberke et al[23] in a single center cohort study of
general hospital population reported the costs attributable to
recurrent CDI over 180 days to be ∼$11,000. Given the age and
illness severity of our population, it is not surprizing that our
estimate was similarly high over a much shorter period of time.
Additionally, in contrast to Dubberke, our >$12,000 excess in
hospital costs (more accurately, Medicare reimbursement) per
patient in the presence of a recurrence includes not only acute, but
also other short-term hospitalizations.
Our study has a number of limitations. As a retrospective study
it is subject to a number of biases, most notably selection bias. To
mitigate this we developed a priori inclusion criteria. Because we
used administrative coding to identify incident CDI, there is a
threat of misclassiﬁcation, though this method of identifying CDI
is well validated in the hospitalized population.[24] One clue to
the extent that it is present is the fact that toxic megacolon, a
complication speciﬁc to CDI, was not conﬁned to the CDI group,
and occurred, albeit with a lower frequency, among non-CDI
patients. However, such misclassiﬁcation likely biased our results
toward the null. Using the ICD-9-CM code for detection of
recurrent CDI is potentially thornier, as this code may or may not
signify the actual presence of active CDI. Wen et al,[25] in a
validations study exploring ways to identify CDI recurrence in
administrative datasets, reported a relatively low speciﬁcity and,
consequently, positive predictive value of a combination of ICD-9
codes, stool-testing procedure codes, and CDI treatment codes
for recurrent CDI. This raises the possibility that a substantial
proportion of those identiﬁed as CDI recurrence were, in fact,
related to the history of CDI rather than an active infection. The
extent of this misclassiﬁcation is difﬁcult to estimate, as the nature
of our study design (all US hospitals as opposed to two academic
urban centers) and population (elderly patients discharged to an
NH after a CDI hospitalization versus all ages followed in the
outpatient clinics afﬁliated with the academic centers) may
invalidate comparisons. Using the MDS dataset to identify CDI
presented its own challenges. Because the current version ofMDS
does not explicitly list CDI as an entity, we had to develop an
algorithm to identify CDI recurrence. Although this algorithm
has never been validated, by requiring CDI-speciﬁc treatment or a
rehospitalization with the principal diagnosis of CDI we
attempted to increase the speciﬁcity of case identiﬁcation.
However, misclassiﬁcation may have led to underestimation of
the rate of recurrence. A source of additional potential
misclassiﬁcation relates to our inability to identify either the
dose or the duration of treatment of the incident CDI episode,
and, thus, inadequately treated cases may have contributed to
recurrence. However, this mimics closely the potential impact of
under-treatment on recurrence in real-world clinical practice.
An additional point where misclassiﬁcation may have occurred
is the 60-day postindex discharge period. Because, unless present
on admission, it is unknown when incident CDI occurred during
the index hospitalization, it is possible that, particularly when the
index hospitalization itself was lengthy, what we classify as a
recurrence is in fact a de novo case of CDI. The fact that our
recurrence rate was well within the range reported in the
literature is reassuring.[26] Additionally reassuring is the fact that
33% is on the higher end of this range, as would be expected in an
older and sicker population. Similarly, this deﬁnition of a
recurrence may account for the high rate of rehospitalization in
the recurrence group. At the same time, it is possible that the null
mortality result is explained at least in part by this high risk of
misclassiﬁcation.
Confounding is an issue in observational studies. Although we
dealt with the possibility of confounding by deriving regression
models to estimate the effect of CDI on the outcomes of interest,
the possibility of residual confounding remains. Because the
timing of events during the index hospitalization was not
available, we had to infer that such events as bowel perforation
and colectomy represented complications of incident CDI. It is,
however, possible that they preceded its occurrence.
These limitations notwithstanding, the size and generalizability
of the dataset, as well as our rigorous statistical methods shed






Cox Hazard ratio 95% Conﬁdence interval
60-day mortality 0.98 0.91 to 1.05
30-day rehospitalization 1.67 1.55 to 1.79
Linear Beta 95% conﬁdence interval
Per ﬁrst post recurrence hospitalization LOS, days 0.9 1.4 to 0.5
Per ﬁrst post recurrence hospitalization costs, $ $316 $1356 to $723
Excess cumulative per patient hospital days within 60 days of recurrence 20.3 19.2 to 21.5
Excess cumulative costs per patient within 60 days of recurrence, $ $12,063 $11,489 to $12,636
LOS= length of stay.
∗
Adjusted for age, gender, race, and comorbid conditions.
Zilberberg et al. Medicine (2017) 96:10 Medicine
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However, our deﬁnitions, and speciﬁcally that of recurrent CDI,
require further validation in a clinical dataset that resembles
population examined here.
At the same time, this study has some major strengths. As the
largest study of its kind, drawing from the entire Medicare
population of the US, its results are highly generalizable. The
novelty of the population examined is of interest. Although these
are the patients known to bring CDI into NHs, ours is the ﬁrst
undertaking to address this population comprehensively. Finally,
by reporting the actualMedicare reimbursements associated with
treatment of this disease, we underscore the ﬁnancial pressures, in
addition to clinical ones, on institutions to target aggressive CDI
prevention measures in this population.
In summary, in the largest study of the Medicare population
addressing a group of patients that acts as a potential reservoir of
CDI in NHs, we have detected a high rate of recurrent CDI.
Although we did not ﬁnd differences in either 60-day mortality,
hospital LOS, or costs per individual rehospitalization event,
recurrent CDI had an important association with the risk of
rehospitalization, thus adding to the cumulative strain on
healthcare resources. Strategies shown to reduce CDI recurrence
should be evaluated as a way not only to improve patient
outcomes, but also to ease the burden on the healthcare system.
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